21 6% af de Tarceva- behandlede patienter, og hver af dem medførte afbrydelse af behandlingen hos 1% af patienterne.
Grade 3/4 rash and diarrhoea occurred in 9% and 6%, respectively in Tarceva-treated patients and each resulted in study discontinuation in 1% of patients.